Laidlaw served as Co-Manager on the $50,000,000 Follow-On Offering for Soleno Therapeutics (SLNO) with Guggenheim Partners

Laidlaw is pleased to have Co-Managed a $50,000,000 deal for Soleno Therapeutics (SLNO) with Guggenheim Partners.

admin2020-08-03T15:14:16+00:00

You are now leaving Laidlaw & Company

This link is provided as a service to you, and will take you to a third party site not affiliated with this site. We are not responsible for the content and do not guarantee the accuracy of any information or material contained therein Laidlaw & Company provides links to web sites of other organizations in order to provide visitors with certain information. A link does not constitute an endorsement of content, viewpoint, policies, products or services of that web site. Once you link to another web site not maintained by Laidlaw & Company, you are subject to the terms and conditions of that web site, including but not limited to its privacy policy.

You will be redirected to

Click the link above to continue or CANCEL

%d bloggers like this:

Laidlaw served as Co-Manager on the $50,000,000 Follow-On Offering for Soleno Therapeutics (SLNO) with Guggenheim Partners

Like this:

Related

You are now leaving Laidlaw & Company

Laidlaw served as Co-Manager on the $50,000,000 Follow-On Offering for Soleno Therapeutics (SLNO) with Guggenheim Partners

Share this:

Like this:

Related

You are now leaving Laidlaw & Company